Question: Exploring the Bristol Myers Squibb and MyoKardia Merger: A Critical Analysis

[20 %]

3. Estimate the market reaction for Bristol Myers Squibb around the acquisition announcement date. From the shareholders’ perspective of the two firms, can the deal be considered successful? Also, estimate the share price reaction of MyoKardia prior to and closely after the acquisition announcement. Discuss your findings.

[20 %]

4. If you were the financial advisor for Bristol Myers Squibb, how much would you advise the management of Bristol Myers Squibb to pay for the acquisition? Estimate the value of MyoKardia in the year prior to the acquisition announcement using at least two valuation methods, one of which should be the DCF method. Clearly demonstrate assumptions, calculations, scenarios and data sources.

[30 %]

5. Compare the estimated value of MyoKardia as estimated in the previous sub-section with the DCF method with its market value on the announcement date. Discuss potential reasons and explanations for the actual payment by Bristol Myers Squibb.

DRAFT / STUDY TIPS:

Exploring the Bristol Myers Squibb and MyoKardia Merger: A Critical Analysis

Introduction

In the ever-evolving landscape of the pharmaceutical industry, strategic mergers and acquisitions have become commonplace. One such significant event occurred on 5th October 2020 when Bristol Myers Squibb (BMS) announced its acquisition of MyoKardia Inc for a staggering $13.1 billion, subsequently completed on 17th November 2020. This paper critically analyzes the background of both companies pre-merger, delves into the motivations behind BMS's decision to acquire MyoKardia, evaluates the market reactions to the merger announcement, and provides insights into the valuation of MyoKardia and the reasons behind the acquisition price.

Background of Bristol Myers Squibb and MyoKardia

Prior to the merger announcement, Bristol Myers Squibb (BMS) and MyoKardia Inc existed as separate entities with distinct financial backgrounds. BMS, established in 1989, is a renowned global biopharmaceutical company with a rich history of innovation and commercial success. With a diverse portfolio spanning oncology, immunology, and cardiovascular drugs, BMS has consistently demonstrated strong financial performance and strategic growth initiatives. Its revenue stream primarily relies on blockbuster drugs such as Opdivo and Eliquis.

On the other hand, MyoKardia Inc, founded in 2012, is a relatively young biotechnology company specializing in the development of precision therapies for cardiovascular diseases. Despite its nascent stage, MyoKardia garnered attention within the industry for its innovative approach towards treating conditions like hypertrophic cardiomyopathy (HCM). However, as a developmental-stage company, MyoKardia's financial standing was characterized by limited revenue streams, primarily derived from collaborations, grants, and potential licensing agreements.

Motivations behind the Acquisition

The decision of Bristol Myers Squibb to acquire MyoKardia was likely influenced by several strategic considerations. Firstly, BMS's interest in MyoKardia can be attributed to the latter's promising pipeline of novel cardiovascular therapies, particularly Mavacamten, a potential treatment for HCM. By integrating MyoKardia's innovative assets into its portfolio, BMS aimed to diversify its product offerings and tap into the lucrative cardiovascular drug market, thus reducing its reliance on existing blockbuster drugs.

Moreover, the acquisition aligned with BMS's long-term strategic goal of expanding its presence in the cardiovascular space. With the patent expiry of key drugs looming on the horizon, BMS sought to replenish its pipeline with innovative therapies capable of sustaining its growth trajectory. MyoKardia's focus on precision medicine and targeted therapies resonated with BMS's commitment to addressing unmet medical needs through scientific innovation.

Furthermore, the synergies between the two companies in terms of research capabilities and expertise likely played a pivotal role in facilitating the acquisition. BMS's global reach and commercialization infrastructure provided MyoKardia with the necessary resources to accelerate the development and commercialization of its pipeline candidates, thereby maximizing shareholder value.

Market Reaction and Shareholder Perspectives

The market reaction to the acquisition announcement can serve as a barometer for evaluating its success from a shareholder perspective. In the days leading up to the announcement, there may have been speculation and anticipation within the market, reflected in fluctuations in BMS's stock price. However, upon the official confirmation of the merger, BMS's stock price experienced a discernible movement, indicative of investor sentiment towards the deal.

From BMS's shareholders' perspective, the acquisition of MyoKardia can be deemed favorable, provided that it generates long-term value and enhances the company's competitive position in the cardiovascular market. However, the success of the deal hinges on BMS's ability to successfully integrate MyoKardia's assets, navigate regulatory challenges, and capitalize on synergies to drive revenue growth and profitability.

Similarly, MyoKardia's shareholders may view the acquisition as a lucrative opportunity to monetize their investments and realize substantial returns. The premium offered by BMS, coupled with the potential for future milestone payments, could outweigh any concerns regarding the loss of independence or the uncertainty associated with transitioning to a larger organization.

Valuation of MyoKardia

As a financial advisor for Bristol Myers Squibb, determining the appropriate acquisition price for MyoKardia would require a comprehensive valuation analysis. Utilizing multiple valuation methods, including Discounted Cash Flow (DCF) and comparable company analysis, would enable a more holistic assessment of MyoKardia's intrinsic value.

In estimating the value of MyoKardia using the DCF method, key assumptions such as revenue projections, discount rate, and terminal growth rate must be carefully considered. By discounting the projected cash flows of MyoKardia's pipeline candidates to their present value, one can ascertain the fair market value of the company. Additionally, conducting sensitivity analyses and scenario planning can provide insights into the range of potential outcomes and mitigate uncertainties inherent in the valuation process.

Furthermore, conducting a comparable company analysis entails benchmarking MyoKardia against peer companies within the biopharmaceutical sector based on key financial metrics such as revenue growth, profitability, and market multiples. By identifying comparable transactions and analyzing their valuation metrics, one can derive a relative valuation for MyoKardia and validate the findings obtained from the DCF analysis.

Comparison of Estimated and Market Values

Discrepancies between the estimated value of MyoKardia derived from the valuation analysis and its market value on the announcement date may stem from various factors. Firstly, market dynamics and investor sentiment can exert significant influence on stock prices, leading to deviations from fundamental valuations. Additionally, the presence of informational asymmetry and speculative behavior within the market may contribute to pricing inefficiencies and discrepancies between estimated and actual values.

Moreover, strategic considerations and non-financial factors, such as synergies, strategic fit, and competitive dynamics, may justify the premium paid by Bristol Myers Squibb for MyoKardia. The strategic value derived from integrating MyoKardia's assets into BMS's portfolio, coupled with the potential for revenue synergies and market expansion, could rationalize the acquisition price from a long-term perspective.

In conclusion, the acquisition of MyoKardia by Bristol Myers Squibb represents a strategic maneuver aimed at bolstering BMS's position in the cardiovascular market and driving sustainable growth. Through a critical analysis of the background of both companies, motivations behind the acquisition, market reactions, and valuation methodologies, this paper provides valuable insights into the intricacies of M&A transactions within the pharmaceutical industry.